Investigators examined the safety and efficacy of metreleptin in patients with congenital or acquired generalized lipodystrophy.
Overall, once-weekly semaglutide 1.0 mg as an add-on to basal insulin is the most efficacious GLP-1 receptor agonist in terms of reductions in HbA1c and body weight from baseline after 6 months of treatment.
Patients initiating DPP-4 inhibitors as third-line therapy in type 2 diabetes appeared to have lower discontinuation rates and less hypoglycemia compared with patients starting NPH insulin.
In this randomized controlled trial, glyburide was not noninferior in terms of the composite rate of macrosomia, neonatal hypoglycemia, and hyperbilirubinemia compared with subcutaneous insulin.
Study compared the real-world effectiveness of canagliflozin 300 mg vs dapagliflozin 10 mg on HbA1c reduction in patients with type 2 diabetes.
Compared to standard insulin treatment, noninsulin antidiabetic agents did not present an increased risk for fetal losses or major malformations when used in the first trimester of pregnancy.
SGLT-2 inhibitors and GLP-1 agonists associated with better mortality outcomes than DPP-4 inhibitors for type 2 diabetesApril 20, 2018
SGLT-2 inhibitors or GLP-1 agonists were associated with lower mortality than DPP-4 inhibitors, placebo, or no treatment. Use of DPP-4 inhibitors was not associated with lower mortality than placebo or no treatment.
Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.
Investigators assessed the association between the cumulative dose of oral glucocorticoid treatment and expense associated with adverse events in patients with rheumatoid arthritis.
Study provides evidence that DPP-4 inhibitors are not associated with an increased risk of acute pancreatitis in older adults overall. The positive association observed in patients with CVD could be due to chance or bias but merits further investigation.
IPITA and EPITA held a workshop to develop consensus for a joint statement on the definition of function and failure of current and future forms of β-cell replacement therapy.
IDegLira provides an efficacious intensification option with noninferior glycemic control vs basal-bolus in patients with type 2 diabetes receiving 20 to 50 units of basal insulin with no renal impairment and HbA1c levels of 7% to 10%.
The composite significant kidney event end point was defined as the first occurrence of ≥30% decline in eGFR to an eGFR <60mL/min/1.73m2, initiation of dialysis or kidney transplant.
The Food and Drug Administration (FDA) has issued a discontinuation notice for Bydureon (exenatide extended-release; AstraZeneca) for injectable suspension Single Dose Trays.
The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.
Bremelanotide, an investigational product, is thought to possess a novel mechanism of action, activating endogenous melanocortin pathways involved in sexual desire and response.
In combination with dietary and physical activity counseling, all semaglutide doses from 0.05-0.4 mg daily were tolerated and resulted in dose-related reductions in body weight among people with obesity without diabetes.
Treating Moderate to Severe Graves' Orbitopathy: Methylprednisolone Alone vs Combined With MycophenolateMarch 14, 2018
This study is the first to investigate the efficacy and safety of add-on mycophenolate to methylprednisolone for moderate to severe Graves' orbitopathy.
Prior authorization requirements are greater for proprotein convertase subtilisin/kexin type 9 inhibitors than for other cardiometabolic drugs.
After induction short-term intensive insulin therapy, metformin is superior to intermittent IIT for maintaining beta-cell function and glycemic control over 2 years.
Antithyroid drug exposure during the first trimester was associated with an increased risk for congenital malformations.
This is the first study to have validated a metformin dose adjustment as a function of the estimated glomerular filtration rate in patients with type 2 diabetes and chronic kidney disease.
Novo Nordisk has announced that the NovoFine 30G 8mm pen needle will be discontinued on or before April 30, 2018.
First trimester exposure to anytithyroid drugs was associated with a greater risk of congenital malformations, especially for pregnant women who were given prescriptions for methimazole or both methimazole and propylthiouracil.
Patients identified with increased insulin resistance following intra-articular corticosteroid injection or any systemic steroid treatment might need a special emphasis regarding management and followup.
For patients with type 2 diabetes undergoing non-cardiac surgery, premedication with liraglutide is associated with reduced median plasma glucose 1 hour postoperatively.
The Food and Drug Administration has accepted the New Drug Application for Azedra for the treatment of malignant, recurrent and/or unresectable pheochromocytoma and paraganglioma.
Steglatro is indicated as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and Steglujan is indicated as adjunct when treatment with both ertugliflozin and sitagliptin are appropriate.
Study aimed to evaluate the benefits of levothytoxine treatment on pregnancy outcomes in subclinical hypothyroid pregnant women who are negative for thyroid peroxidase antibody.
Study sought to determine the optimal dosing of linagliptin for the treatment of children with type 2 diabetes.
Endocrinology Advisor Articles
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Dulaglutide Effective for Patients With T2D, Moderate to Severe CKD
- Incidence of Diabetes Influenced by Endocrine-Disrupting Chemicals in the Environment
- Guidelines for Management of Hypothalamic-Pituitary, Growth Disorders in Childhood Cancer Survivors
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- New Romosozumab BLA Includes Data from Additional Osteoporosis Trials
- Impact of Maternal Diabetes on Outcomes in Very Preterm, Very Low-Birth-Weight Infants
- Age-Related Differences in Manifestation of Cushing Disease Identified